Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment

Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment

Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment

Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.